Tau-Targeting Alzheimer’s Drug from AC Immune, Roche Fails in Phase 2
Summary
An Alzheimer’s disease drug from partners AC Immune and Roche has failed a mid-stage clinical trial, adding another compound to the list of experimental therapies that have fallen short of demonstrating that they can treat the neurodegenerative disorder. It did not achieve the Phase 2 study’s main goal of beating a placebo in slowing decline according to a dementia scale, AC Immune (NASDAQ: ACIU) reported Wednesday. The company added that the drug also failed to beat a placebo in secondary goals of showing improvement in cognitive symptoms and the ability to perform the activities of daily living. In a prepared statement, AC Immune CEO Andrea Pfeifer said the results were “surprising and disappointing,” given what the Alzheimer’s field knows about tau and the correlation of the protein buildup to the symptoms and progression of the disease. SVB Leerink analyst Marc Goodman wrote in a note to investors that the results are disappointing to the company and to the Alzheimer’s community, as the study was hoped to validate the anti-tau antibody approach to treating the disease.
Classifications
AskAI Classifications
LabelsLinked Companies
